GSK (NYSE: GSK) executive sells 100,000 shares on London Stock Exchange

Rhea-AI Filing Summary

GSK plc filed a Form 6-K reporting two insider share sales on the London Stock Exchange. David Redfern, President of Corporate Development, sold 100,000 ordinary shares at £21.09 per share on 2026-02-05.

On the same date, Neil Falkingham, a person closely associated with Lynn Baxter (President, Europe), sold 2,000 ordinary shares at £20.87 per share. Both transactions involved GSK ordinary shares of 31¼ pence each and were executed on XLON.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	David Redfern
b)	Position/status	President, Corporate Development
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Sale of 100,000 Ordinary Shares
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.0900	100,000
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-02-05
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Neil Falkingham
b)	Position/status	PCA of Lynn Baxter (President, Europe)
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Sale of 2,000 Ordinary Shares
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£20.8700	2,000
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-02-05
f)	Place of the transaction	London Stock Exchange (XLON)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: February 05, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What insider transactions did GSK (GSK) disclose in this Form 6-K?

GSK disclosed two insider share sales. David Redfern sold 100,000 ordinary shares at £21.09, and Neil Falkingham, a person closely associated with an executive, sold 2,000 shares at £20.87, both on the London Stock Exchange on 2026-02-05.

Who is David Redfern and how many GSK shares did he sell?

David Redfern is GSK’s President, Corporate Development. He sold 100,000 ordinary shares of GSK at a price of £21.09 per share on 2026-02-05, in a single transaction executed on the London Stock Exchange (XLON).

What transaction was reported for Neil Falkingham related to GSK (GSK)?

Neil Falkingham, a person closely associated with Lynn Baxter (President, Europe), sold 2,000 GSK ordinary shares at £20.87 per share on 2026-02-05. This was reported as a single transaction on the London Stock Exchange under GSK’s Form 6-K.

On which market were the reported GSK insider share sales executed?

Both reported GSK insider share sales were executed on the London Stock Exchange, identified as XLON. The transactions involved ordinary shares of 31¼ pence each, sold at £21.09 and £20.87 per share respectively on 2026-02-05.

What type of shares were involved in the GSK insider transactions?

The transactions involved GSK ordinary shares of 31¼ pence each, identified by ISIN GB00BN7SWP63. Both David Redfern and Neil Falkingham sold these ordinary shares on the London Stock Exchange in single transactions on 2026-02-05.

Does this GSK (GSK) filing involve multiple transactions per insider?

No. Each insider’s activity is reported as a single transaction. David Redfern’s 100,000-share sale and Neil Falkingham’s 2,000-share sale are each described as aggregated information not applicable because only one transaction occurred per individual on 2026-02-05.